11β-hydroxylase deficiency surgery: Difference between revisions
No edit summary |
No edit summary |
||
Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{Ammu}} | {{CMG}}; {{AE}} {{Ammu}} | ||
==Overview== | ==Overview== | ||
The predominant therapy for ambigous genitalia in congenital adrenal hyperplasia due to 11β-hydroxylase deficiency is surgical correction. | |||
==Surgery== | ==Surgery== | ||
* Suregry is used to correct ambigous genitalia. | * Suregry is used to correct ambigous genitalia. |
Revision as of 19:16, 28 January 2016
Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency Microchapters |
Differentiating Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
11β-hydroxylase deficiency surgery On the Web |
American Roentgen Ray Society Images of 11β-hydroxylase deficiency surgery |
Directions to Hospitals Treating Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency |
Risk calculators and risk factors for 11β-hydroxylase deficiency surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
The predominant therapy for ambigous genitalia in congenital adrenal hyperplasia due to 11β-hydroxylase deficiency is surgical correction.
Surgery
- Suregry is used to correct ambigous genitalia.
Indications
- Ambigous genitalia
References